Perrigo could have an oversold bounce at any time as bears turn aggressive, but nothing right now indicates a price bottom.
Valeant shares jumped Tuesday on renewed hopes that a management reshuffle will help turn around shares.
His bet on Valeant is proving to be disastrous.
The market is struggling to properly estimate the value of Valeant's core assets, Bill Ackman says.

4 Possible Biotech M&A Targets Real Money Pro($)

These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.
Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.
The drug maker is approaching overbought territory, but is set up well for more upside.
Prices are above the rising 50-day simple moving average line -- a plus.
We recently got a golden cross of the 50-day and 200-day averages.
The M&A activity is an incredible and a welcome sign.

Columnist Conversations Interesting panel on media now.
Greenlight's Einhorn targets Caterpillar as a short. And I agree.
Tesla estimates that capital spending will be about 50% higher than expectations. Could this result in a bond/...
Will a TSLA financing be announced coincident with EPS tonite? Stay tuned!


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.